Use of the new pneumococcal conjugate vaccine in the USA

Archives of Disease in Childhood

Volumn 83, Issue 5, 2000, Pages 396-

  Baucher, H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG COST; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; OTITIS MEDIA; PRIORITY JOURNAL; SEROTYPE; SHORT SURVEY; SICKLE CELL ANEMIA; SPLEEN DISEASE; STREPTOCOCCUS INFECTION; TYMPANOSTOMY TUBE; UNITED STATES;

CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0033761542     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.83.5.396     Document Type: Short Survey

References (2)

1. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
2. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis